Blunted humoral response to influenza vaccination in patients exposed to zidovudine plus trimethoprim-sulfamethoxazole

Pharmacotherapy

Volumn 27, Issue 7, 2007, Pages 937-947

  Feola, David J ^a,b   Garvy, Beth A ^a   Rapp, Robert P ^a   Thornton, Alice C ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b University of Kentucky   (United States)

Author keywords

Adverse drug reactions; Antiretroviral therapy; HIV; Human immunodeficiency syndrome; Immunology

Indexed keywords

COTRIMOXAZOLE; IMMUNOGLOBULIN G ANTIBODY; INFLUENZA VACCINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; DRUG RESPONSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; INFLUENZA VACCINATION; MALE; MONOTHERAPY; OPEN STUDY; OUTPATIENT DEPARTMENT; PROSPECTIVE STUDY; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA VACCINES; MALE; MIDDLE AGED; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; ZIDOVUDINE;

EID: 34250896061     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.7.937     Document Type: Article

References (29)

1. Martinez-Maza O, Crabb E, Mitsuyasu RT, Fahey JL, Giorgi JV. Infection with the human immunodeficiency virus (HIV) is associated with an in vivo increase in B lymphocyte activation and immaturity. J Immunol 1987;138:3720-4.
2. Lane HC, Masur H, Edgar LC, Whalen G, Rook AH, Fauci AS. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med 1983;309:453-8.
3. Atnmann AJ, Schiffman G, Abrams D, Volberding P, Ziegler J, Conant M. B-cell immunodeficiency in acquired immune deficiency syndrome. JAMA 1984;251:1447-9.
4. Simberkoff MS, El Sadr W, Schiffman G, Rahal JJ Jr. Streptococcus pneumoniae infections and bacteremia in patients with acquired immune deficiency syndrome, with report of a pneumococcal vaccine failure. Am Rev Respir Dis 1984;130: 1174-6.
5. Bernstein LJ, Ochs HD, Wedgwood RJ, Rubinstein A. Defective humoral immunity in pediatric acquired immune deficiency syndrome. J Pediatr 1985;107:352-7.
6. Ballet JJ, Sulcebe G, Couderc LJ, et al. Impaired antipneumococcal antibody response in patients with AIDS-related persistent generalized lymphadenopathy Clin Exp Immunol 1987;68:479-87.
7. Janoff EN, Douglas JM Jr, Gabriel M, et al. Class-specific antibody response to pneumococcal capsular polysaccharides in men infected with human immunodeficiency virus type I. J Infect Dis 1988;158:983-90.
8. Dawood MR, Conway B, Patenaude P, et al. Association of phenotypic changes in B cell lymphocytes and plasma viral load in human immunodeficiency virus-infected patients. J Clin Immunol 1998;18:235-40.
9. Wolthers KC, Otto SA, Lens SM, Van Lier RA, Miedema F, Meyaard L. Functional B cell abnormalities in HIV type 1 infection: role of CD40L and CD70. AIDS Res Hum Retroviruses 1997;13:1023-9.
10. Kaplan JE, Masur H, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons-2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep 2002;51(RR-8):1-52.
11. Amendola A, Boschini A, Colzani D, et al. Influenza vaccination of HIV-1-positive and HIV-1-negative former intravenous drug users. J Med Virol 2001;65:644-8.
12. Sorvillo FJ, Nahlen BL. Influenza immunization for HIV-infected persons in Los Angeles. Vaccine 1995;13:377-80.
13. Fowke KR, D'Amico R, Chernoff DN, et al. Immunologic and virologic evaluation after influenza vaccination of HIV-1-infected patients. AIDS 1997;11:1013-21.
14. Kroon FP, Rimmelzwaan GF, Roos MT, et al. Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy. AIDS 1998;12:F217-23.
15. Kroon FP, van Dissel JT, de Jong JC, Zwinderman K, van Furth R. Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine 2000;18:3040-9.
16. Iorio AM, Francisci D, Camilloni B, et al. Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy. Vaccine 2003;21:3629-37.
17. Feola DJ, Garvy BA. Zidovudine plus sulfamethoxazole-trimethoprim adversely affects B lymphocyte maturation in bone marrow of normal mice. Int Immunopharmacol 2005;5:1881-94.
18. Freund YR, Dousman L, MacGregor JT, Mohagheghpour N. Oral treatment with trimethoprim-sulfamethoxazole and zidovudine suppresses murine accessory cell-dependent immune responses. Toxicol Sci 2000;55:335-42.
19. Furman PA, Fyfe JA, St Clair MH, et al. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 1986;83:8333-7.
20. Naisbitt DJ, Hough SJ, Gill HJ, Pirmohamed M, Kitteringham NR, Park BK. Cellular disposition of sulphamethoxazole and its metabolites: implications for hypersensitivity. Br J Pharmacol 1999;126:1393-407.
21. Feola DJ, Garvy BA. Combination exposure to zidovudine plus sulfamethoxazole-trimethoprim diminishes B-lymphocyte immune responses to Pneumocystis murina infection in healthy mice. Clin Vaccine Immunol 2006;13:193-201.
22. Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB. Prevention and control of influenza: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 2004;53(RR-6):1-40.
23. Beyer WE, Palache AM, de Jong JC, Osterhaus AD. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy: a meta-analysis. Vaccine 2002;20:1340-53.
24. McHeyzer-Williams MG, Ahmed R. B cell memory and the long-lived plasma cell. Curr Opin Immunol 1999;11:172-9.
25. Lane R Traunecker A, Hubele S, Inui S, Lanzavecchia A, Gray D. Activated human T cells express a ligand for the human B cell-associated antigen CD40 which participates in T cell-dependent activation of B lymphocytes. Eur J Immunol 1992;22:2573-8.
26. Snapper CM, Kehry MR, Castle BE, Mond JJ. Multivalent, but not divalent, antigen receptor cross-linkers synergize with CD40 ligand for induction of Ig synthesis and class switching in normal murine B cells: a redefinition of the TI-2 vs T cell-dependent antigen dichotomy J Immunol 1995;154:1177-87.
27. Croft M, Swain SL. B cell response to fresh and effector T helper cells: role of cognate T-B interaction and the cytokines IL-2, IL-4, and 1L-6. J Immunol 1991;146:4055-64.
28. Kelsoe G. The germinal center: a crucible for lymphocyte selection. Semin Immunol 1996;8:179-84.
29. Gilkeson GS, Bernstein K, Pippen AM, et al. The influence of variable-region somatic mutations on the specificity and pathogenicity of murine monoclonal anti-DNA antibodies. Clin Immunol Immunopathol 1995;76(1 pt 1):59-67.